News Releases

2014

XXX
Dec.26.2014
Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration(134KB)
XXX
Dec.19.2014
ONO AND GILEAD ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO DEVELOP BTK INHIBITOR, ONO-4059, FOR THE TREATMENT OF B-CELL MALIGNANCIES AND OTHER DISEASES(36.2KB)
XXX
Dec.11.2014
ONO Establishes a Local Subsidiary in Taiwan(60.6KB)
XXX
Dec.10.2014
ONO PHARMACEUTICAL, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors(37.4KB)
XXX
Dec.10.2014
Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma(117KB)
XXX
Nov.19.2014
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naive Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial(85.8KB)
XXX
Nov.05.2014
ONO files an application for RIVASTACH® PATCH for adding dosage and administration in Japan(27.8KB)
XXX
Nov.05.2014
Announcement on Financial Results for FY2014 2Q
XXX
Oct.31.2014
Phase 2 Objective Response Rates and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology(111KB)
XXX
Oct.31.2014
Helsinn Group, Switzerland, announced new data on Fatigue from Phase III Trial (ROMANA 1) of Anamorelin/ONO-7643 in patients with Cancer Anorexia-Cachexia Syndrome (CACS) associated with Non-Small Cell Lung Cancer at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology(105KB)
XXX
Oct.29.2014
Establishment of GPCR Consortium, a New International Partnership, to Advance Structural Information about G-protein Coupled Receptors(341KB)
XXX
Oct.08.2014
Revisions of Consolidated Financial Forecasts(19.2KB)
XXX
Oct.07.2014
Approval for the Stability-Improved Formulation of Limaprost, an Oral Prostaglandin E1 Analogue in Japan(36.3KB)
XXX
Oct.03.2014
European Medicines Agency Validates the Marketing Authorization Application for Opdivo (Nivolumab) in Non-Small Cell Lung Cancer(77.4KB)
XXX
Oct.02.2014
Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union(73.1KB)
XXX
Sep.30.2014
Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy® (ipilimumab) Presented at the ESMO 2014 Congress(136KB)
XXX
Sep.29.2014
Helsinn Group, Switzerland, announced the results of Phase III Trials (ROMANA 1 and ROMANA 2) of Anamorelin/ONO-7643 in patients with Cancer Anorexia-Cachexia Syndrome (CACS) associated with Non-Small Cell Lung Cancer(144KB)
XXX
Sep.02.2014
Human Anti-human PD-1 Monoclonal Antibody OPDIVO® Intravenous Infusion 20 mg/100 mg launches in Japan for Treatment of Unresectable Melanoma(179KB)
XXX
Aug.20.2014
Announcement of top-line results from Phase 3 FOCUS Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed and advanced refractory multiple myeloma(81.8KB)
XXX
Aug.11.2014
Phase 3 ASPIRE Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed multiple myeloma met primary endpoint (Progression-free survival)(200KB)
XXX
Aug.04.2014
Announcement on Financial Results for FY2014 1Q
XXX
July.28.2014
Ono and Meiji Seika Pharma enter into an agreement on development and ommercialization of Limaprost in Thailand and Indonesia(26.2KB)
XXX
July.24.2014
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan(85.8KB)
XXX
July.11.2014
Human Anti-human PD-1 Monoclonal Antibody OPDIVO® Bristol-Myers Squibb plans for Third Quarter Submission of a Biologics License Application for Previously Treated Advanced Melanoma(236KB)
XXX
July.09.2014
Ono Enters into the Collaboration Agreement with the University of Tokyo regarding Access to Ono's Compound Library(29.8KB)
XXX
July.04.2014
Human Anti-human PD-1 Monoclonal Antibody "OPDIVO® Intravenous Infusion 20 mg/100 mg" Receives Manufacturing and Marketing Approval in Japan for the Treatment of Unresectable Melanoma(53.2KB)
XXX
Jun.27.2014
Notice to Resolutions Passed at the 66th Ordinary General Shareholders' Meeting
XXX
Jun.25.2014
2014Fully Human Anti-PD-1 Antibody Nivolumab ("ONO-4538/BMS-936558") Demonstrates Superior Overall Survival Compared to Dacarbazine in Phase 3 First-Line Melanoma Study (CheckMate -066)(177KB)
XXX
Jun.17.2014
Termination of the license agreement for ONO-4641 mutually agreed by Ono and Merck(40.4KB)
XXX
Jun.05.2014
Notice to Convene the 66th Ordinary General Shareholders' Meeting
XXX
Jun.03.2014
Fully Human Anti-PD-1 Antibody “ONO-4538/BMS-936558”Results from Phase 1 Study in Patients with Melanoma Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)(70.3KB)
XXX
May.23.2014
Glactiv® has obtained the approval of the partial change in the indications of "type 2 diabetes"(28.9KB)
XXX
May.23.2014
FORXIGAR® launches in Japan for the treatment of Type 2 diabetes(99.9KB)
XXX
May.13.2014
Position and policies concerning the reduction of the minimum investment unit(21.4KB)
XXX
May.13.2014
Announcement on Candidates of Members of the Board of Directors and Corporate Officers(38.9KB)
XXX
May.13.2014
Announcement on Financial Results for FY2013
XXX
Apr.30.2014
Discontinuation of the license agreement for a new therapeutic agent for thrombocytopenia(16.1KB)
XXX
Mar.24.2014
FORXIGA® (dapagliflozin) receives regulatory approval in Japan for the treatment of Type 2 diabetes(94.1KB)
XXX
Mar.06.2014
ONO establishes an innovative research network called "Orientem Innovation" together with Tohoku University & The University of Tokyo(165KB)
XXX
Feb.04.2014
Announcement on Financial Results for FY2013 3Q
XXX
Jan.17.2014
Annoucement on CSR Report 2013